Paper Details

  1. Home
  2. Paper Details

Pharmacological characterization of naloxegol: In vitro and in vivo studies.

Author: CalòGirolamo, CostanziniAnna, De GiorgioRoberto, MalfaciniDavide, NetoJoaquim Azevedo, RuzzaChiara, SterniniCatia, SturaroChiara

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study compared the pharmacological characteristics of naloxegol, a peripherally acting mu opioid receptor antagonist, to naloxone. Naloxegol effectively countered the constipating effects of fentanyl without interfering with its analgesic effects, suggesting its potential as a safe and effective treatment for opioid-induced constipation.
Paper Details　
Original Abstract of the Article :
Opioid-induced constipation is the most prevalent adverse effect of opioid drugs. Peripherally acting mu opioid receptor antagonists (PAMORAs), including naloxegol, are indicated for the treatment of opioid-induced constipation. The aim of this study was the in vitro and in vivo pharmacological char...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejphar.2021.174132

データ提供：米国国立医学図書館（NLM）

Naloxegol: A Peripheral Mu Opioid Receptor Antagonist

The use of opioids for pain management can often come with unwanted side effects, particularly constipation. This study investigates the pharmacological properties of a novel medication called naloxegol, a peripherally acting mu opioid receptor antagonist (PAMORA), designed specifically to target opioid-induced constipation.

Researchers carefully examined the actions of naloxegol both in vitro and in vivo, comparing its effects to those of naloxone, a more traditional opioid antagonist. Their findings suggest that naloxegol, unlike naloxone, can effectively relieve opioid-induced constipation without affecting the pain-relieving properties of opioids. This selectivity makes it a promising candidate for treating this common side effect of opioid therapy.

Targeted Relief from Opioid-Induced Constipation

The study highlights the potential of naloxegol to provide targeted relief from opioid-induced constipation, without compromising the benefits of opioid pain management. This selective approach represents a significant advancement in the management of opioid side effects.

Improved Opioid Therapy

Imagine a world where individuals can reap the benefits of opioid pain management without the uncomfortable side effects of constipation. Naloxegol, with its targeted action, offers a potentially life-changing solution for patients who experience this common issue.

Dr. Camel's Conclusion

The development of naloxegol represents a significant step forward in the management of opioid-induced constipation. This PAMORA offers a targeted approach to relieving this common side effect, allowing individuals to benefit from opioid pain management without the discomfort and inconvenience of constipation.

Date :
  1. Date Completed 2021-10-22
  2. Date Revised 2021-10-22
Further Info :

Pubmed ID

33933466

DOI: Digital Object Identifier

10.1016/j.ejphar.2021.174132

Related Literature

Article Analysis
・Effects of naloxegol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.